Aligos Therapeutics, Inc. 8-K

What Happened
Aligos Therapeutics, Inc. filed an 8-K reporting that at its Annual Meeting of Stockholders on June 25, 2026, stockholders approved an amendment to the company’s 2020 Employee Stock Purchase Plan (ESPP). The Board had approved the amendment on April 22, 2026 and it became effective upon stockholder approval. The amendment (the “Amended ESPP”) (i) reserves an additional 500,000 shares for issuance under the plan, including for the offering period that began November 15, 2025, and (ii) eliminates the ESPP’s “evergreen” provision so the share reserve is now a fixed number and will not automatically increase in future years.

Key Details

• Annual Meeting date: June 25, 2026; Board approval date: April 22, 2026.
• Added 500,000 shares to the ESPP share reserve.
• Evergreen provision removed — future automatic annual increases to the reserve have been eliminated.
• Amendment text is filed as Exhibit 10.1 to the Form 8‑K; details were described in the company’s Proxy Statement (filed April 29, 2026).

Why It Matters
For investors, the amendment can affect potential dilution: adding 500,000 shares increases the number of shares that may be issued under the ESPP if participants purchase them. Removing the evergreen feature limits future automatic increases to the plan’s share reserve, making any further increases subject to separate approvals (rather than automatic annual boosts). The change is primarily about employee compensation and equity incentive capacity rather than operating performance.